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Background. Small colony variants of Staphylococcus aureus tend to persist despite antimicrobial therapy,
especially when involved in implant-associated infections.
Methods. We analyzed 5 cases of hip prosthesis–associated infections due to small colony variants, including
their course prior to identification of the pathogen. Biopsy investigations included microbiological examination
and, in 1 case, transmission electron microscopy to detect intracellular bacteria in nonprofessional phagocytes. A
treatment concept was elaborated on the basis of a published algorithm and patients were managed accordingly.
Results. The patients’ mean age was 62.2 years. All patients experienced treatment failures prior to isolation
of small colony variants, despite as many as 3 surgical revisions and up to 22 months of antibiotics. Transmission
electron microscopy performed on biopsy specimens from periprosthetic tissue revealed intracellular cocci in
fibroblasts. All prostheses were removed without implanting a spacer, and antimicrobial agents were administered
for 5.5–7 weeks. Reimplantation of the prosthesis was performed for 4 patients. Follow-ups were uneventful in
all 5 cases.
Conclusions. In the case of a poor response to adequate antimicrobial and surgical treatment in implant-
associated staphylococcal infections, small colony variants should be considered and actively sought. In our case
series, a 2-stage exchange without implantation of a spacer combined with antimicrobial therapy for an implant-
free interval of 6–8 weeks was associated with successful outcome, with a mean follow-up of 24 months.
Small colony variants (SCVs) are naturally occurring
subpopulations of Staphylococcus aureus and are asso-
ciated with persistent or recurrent infection. They differ
from normal-phenotype S. aureus of not only in their
small colony sizes (because of their slow rate of growth)
but also by decreased pigmentation and hemolysis.
These characteristics are based on auxotrophisms for
thymidine, menadione, or hemin, which lead to a de-
ficiency in electron transport [1]. These variants are
difficult to treat because of their increased resistance to
aminoglycosides and to cell-wall–active antibiotics, as
well as their ability to persist. To date, intracellular per-
sistence of SCVs has been demonstrated in vitro but
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not ex vivo [2]. Because SCVs are often relatively un-
stable and can revert to the highly virulent and rapid-
growing form, these variants are difficult to identify.
SCVs have been described in cases of sepsis [3, 4],
cystic fibrosis [5, 6], soft-tissue infection [2, 3, 7, 8],
osteomyelitis [3, 8–11], arthritis [8, 12], brain abscess
[13], sinusitis [8], and in some foreign body–associated
infections (including infections associated with osteo-
synthesis [14], pacemaker [15], and ventriculoperito-
neal shunt [16]). To our knowledge, there have been
no reports of SCVs associated with prosthetic joint in-
fection (PJI); therefore, no treatment concepts have
been recommended or tested.
We present 5 cases of PJI caused by SCVs, and we
review their clinical courses before and after isolation
of SCVs. We also investigated biopsy specimens ob-
tained from the joint capsule of 1 patient by trans-
mission electron microscopy for the intracellular pres-
ence of naturally occurring SCVs in nonprofessional
phagocytes. The main aims of this study were to present
a rational treatment concept for the management of
SCVs in PJI using a previously published algorithm [17]
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and to control the outcome of this management with regular
follow-up visits.
PATIENTS AND METHODS
The 5 cases were identified among 83 PJIs (associated with 66
total hip and 17 total knee arthroplasties) occurring in our
institution from January 2002 through December 2005. Our
orthopedic surgery clinic is a 48-bed unit that acts as a primary
care center for all types of orthopedic surgery of the extremities,
as well as a tertiary care center for patients needing revision
arthroplasty.
Case history. Patient charts were reviewed to evaluate each
patient’s first infection period with S. aureus, including the
location of primary focus, the presence of bacteremia, and the
number and location of prosthetic joints and their involvement
in the infection. The number of surgical revisions and the length
of antibiotic therapy in months prior to the detection of SCVs
were documented. The interval between completing antibiotic
therapy and relapse of SCV infection was analyzed.
Identification of SCVs. Specimens were isolated from joint
aspiration and/or intraoperative tissue and cultured on Colum-
bia blood agar. SCVs were identified by the following pheno-
typical characteristics: (1) slow growth, (2) small colonies, (3)
decreased pigmentation, and (4) weak hemolysis on Columbia
blood agar. S. aureus species testing included the presence of
growth on S. aureus ID agar, the use of the ID color catalase
test Slidex Staph Plus (bioMe´rieux), and PCR for the S. aureus–
specific gene femA.
Susceptibility testing. PCR for the mecA gene was per-
formed to detect methicillin resistance [18]. MICs were ex-
amined using Etest (AB Biodisk) on Muller-Hinton and Muller-
Hinton blood agar. The plates were incubated at 35C and read
after 48 and 72 h.
Genotypic analysis. SmaI digests of chromosomal DNA of
SCVs and of the simultaneously occurring normal phenotype
were analyzed by PFGE to prove clonal identity.
Ex vivo investigations for intracellular bacteria in peri-
prosthetic tissue. In patient 5, 7 biopsy samples were obtained
during removal of the prosthesis. Each biopsy sample was di-
vided into 2 parts: 1 part for microbiological and 1 part for
histological investigation. Three biopsy samples obtained from
the joint capsule grew SCV monocultures. Tissue samples were
punched from the 3 corresponding histological paraffin blocks
and exposed to a temperature of 60C for 60 min. The spec-
imens were first immersed in xylol ( min) and absolute2 15
alcohol ( min) and then in a descending alcohol series2 15
(90%, 70%, and 50% by volume; 15 min each). After tissues
were washed in phosphate buffer solution, they were fixed with
1% OsO4 solution for 60 min. Next, specimens were dehydrated
in an ascending alcohol series (50%, 70%, and 90% by volume
and absolute alcohol; 15 min each) and acetone (60 min). An
infiltration process was performed first with a 1:1 mixture of
epon and acetone (60 min) and then with epon alone (240
min). Polymerization was allowed to continue for 24 h at a
temperature of 60C. Samples were then sliced with an ultra-
microtome (Reichert-Jung Ultracut E). The 60- to 70-nm–thick
slices were analyzed by transmission electron microscopy (FEI,
Philips, Morgani 268D).
Treatment. Patient treatment was based on a previously
published algorithm for difficult-to-treat microorganisms [17].
In this protocol, the infected prosthesis and all foreign material
are completely removed without implanting a spacer, and me-
ticulous debridement of the infected tissue is performed. To
prevent soft tissue contraction, hip traction is performed with
the aid of a Steinmann pin inserted through the distal end of
the femur. During the implant-free interval, antibiotics are ad-
ministered for 6 weeks, and reimplantation of the prosthesis is
performed after 2 further antibiotic-free weeks. After reim-
plantation, the same antibiotic regimen administered during
the implant-free interval is administered again, until newly ob-
tained biopsies from the periprosthetic tissue are reported to
be negative (normally after 14 days). In methicillin-susceptible
staphylococcal infections, flucloxacillin is administered intra-
venously after removal of the prosthesis, but it is switched to
a combination of rifampin plus levofloxacin within a few days.
Rifampin has bactericidal activity against surface-adhering,
slow-growing, and biofilm-producing microorganisms, but it
should not be administered alone [19, 20]. Quinolones are
excellent in combination with rifampin because of their bio-
availability, antimicrobial activity, and tolerability [21]. In cases
of resistance, decisions about antibiotics are made on an in-
dividual basis according to MICs.
Outcomes. Follow-up analyses included clinical examina-
tions, laboratory testing (determination of C-reactive protein
levels and WBC counts), and radiological examinations. Cure
was defined as treatment failure–free survival for at least 24
months, and a probable cure was defined as treatment failure–
free survival with a follow-up of !24 months [22].
RESULTS
Clinical course prior to isolation of SCVs. Data on clinical
course prior to isolation of SCVs are presented in table 1. We
identified 5 male patients who had total-hip arthroplasty–
related infections caused by SCVs. Their mean age was 62.2
years (range, 51–71 years). Patients 2, 4, and 5 received bilateral
prostheses and patients 1 and 3 each received a unilateral hip
prosthesis. Clinical signs of sepsis and blood cultures positive
for S. aureus were documented for patients 3, 4, and 5. Hence,
patient 4 and 5 had bilateral hip prostheses and documented
S. aureus bacteremia. In these 2 patients, both prostheses were
involved in the infection.
In patient 4, the pathogen had seeded to the contralateral
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Table 1. Clinical course prior to isolation of Staphylococcus aureus small colony variants.
Patient characteristic and
treatment Patient 1 Patient 2 Patient 3 Patient 4a Patient 5b
Age, years 55 70 59 71 51
Side of hip prosthesis Left Both Left Both Both
Focus of primary Staphylococcus
aureus infection
Hip prosthesis Left hip prosthesis Hip prosthesis Right hip prosthesis Left hip prosthesis
Staphylococcus aureus bacteremia No No Yes Yes Yes
Contralateral prosthesis involved … No … Yes Yes
No. of surgical revisions performed 2 1 1 Right hip, 3; left hip, 5 0
No. of months receiving antibiotics 4 6 19 22 6
Antimicrobial agents FLUCLOX, switched
to CIP and RIF
FLUCLOX, switched
to CIP and RIF
VAN and FEP, switched
to CIP and RIF
CIP and RIF CIP and RIF
Length of relapse-free interval after
completing antibiotic therapy
3 months 3 months Persistent infection 13.5 months 23 months
NOTE. CIP, ciprofloxacin; FEP, cefepime; FLUCLOX, flucloxacillin; RIF, rifampin; VAN, vancomycin.
a Patient 4 suffered from prosthesis-associated infection of the left hip shortly after the primary infection (right hip prosthesis). The left side was surgically
revised 5 times but, despite prolonged antimicrobial treatment (22 months), the infection persisted and was secondarily colonized with Pseudomonas aeruginosa.
After a spacer-free, 2-stage exchange and antibiotic therapy during the implant-free interval, the infection was healed. Relapse of infection with small colony
variants occurred at the primary (right) side of infection 13.5 months after completion of treatment for infection in the left side.
b Patient 5 was treated with a spacer-free, 2-stage exchange for prosthetic joint infection of the left hip. During the implant-free interval of 6 months, he
received ciprofloxacin and rifampin; 23 months later, small colony variants were isolated from synovia of the previously inconspicuous right hip prosthesis.
hip prosthesis during bacteremia. The side on which primary
infection occurred was considered to be healed after 3 surgical
revisions, but infection persisted on the contralateral side for
22 months, despite 5 surgical revisions and antibiotic therapy.
Healing was achieved after a spacer-free, 2-stage exchange, but
this was followed by another relapse at the primary infection
site 13.5 months later, where SCVs were finally isolated.
Patient 5 suffered from joint pain for several weeks prior to
presenting with S. aureus sepsis due to PJI of the left hip. It is
very likely that SCVs were seeding from the primary focus of
infection to the right hip prosthesis during the bacteremia [23];
in the absence of symptoms, however, joint puncture was not
performed, and 18 months later, the patient suffered from joint
pain of the right hip. Finally, SCVs were isolated from this hip
prosthesis, 5 months later and 23 months after completion of
therapy for infection in the left hip.
Treatment prior to isolation of SCVs. Patients experienced
up to 3 surgical revisions on the side of SCV isolation and up
to 22 months of antimicrobial treatment. All patients ultimately
received ciprofloxacin and rifampin; prior to receiving this reg-
imen, 2 patients were treated with flucloxacillin, and 1 received
vancomycin plus cefepime.
Relapse-free interval. In patients 1 and 2, relapse occurred
3 months after completing therapy. Patient 3 experienced per-
sistent infection; several attempts to withdraw antibiotics
prompted flare ups, and he was, therefore, treated with sup-
pressive therapy for 19 months. As outlined above, patient 4
experienced relapse after 13.5 months, and patient 5 experi-
enced relapse 23 months after completing therapy for the con-
tralateral hip prosthesis infection.
The characteristics of isolated microorganisms are shown in
table 2. Joint puncture was performed prior to surgery in 4
patients; in 3 of these, SCVs were detected in synovial culture.
Culture results. SCVs grew on Columbia blood agar after
2–3 days, revealing small colonies, decreased pigmentation, and
weak hemolysis. Mixed cultures of normal-phenotype S. aureus
and SCVs were present in patients 1–3. For patients 4 and 5,
SCV monocultures grew in synovial cultures, but cultures of
biopsy specimens taken during subsequent surgery showed
both SCV and normal-phenotype S. aureus. On S. aureus ID
agar, pathogens grew either as SCVs or as the normal phenotype
after 24 h of incubation.
Susceptibility testing. All pathogens were methicillin sus-
ceptible and lacked the mecA gene. Two strains were resistant
to trimethoprim-sulfamethoxazole without previous treatment
with this compound (patients 1 and 2). One SCV subculture
was resistant to rifampin (patient 5), and 1 was resistant to
both ciprofloxacin and rifampin (patient 4).
Genotypic analysis. PCR for the femA gene was positive
in all cases. PFGE demonstrated the clonal identity of the nor-
mal phenotype and SCVs (figure 1) in all cases. In patient 1,
clonal identity was additionally shown for the primary infec-
tion; in the other 4 patients, pathogens from primary infections
were not available.
Transmission electron microscopy. Investigations of biopsy
specimens obtained from patient 5 showed the presence of
intracellular bacteria in nonprofessional phagocytes (figure 2).
These cells were identified as fibroblasts.
Treatment. After removal of the prosthesis, a spacer was
implanted in 2 patients, because SCVs either had not been
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Table 2. Characteristics of Staphylococcus aureus small colony variants (SCVs) and treatment of patients.
Characteristic Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Growth on Columbia blood agar, days NAa 2 2 3 2
Method of detection Joint puncture Biopsies Biopsiesb Joint puncture Joint puncture
Monocultures of SCVs No No No Yesc Yesc
Presence of femA gene Yes Yes Yes Yes Yes
Clonal identity with normal phenotype
by PFGE
Yes Yes Yes Yes Yes
Presence of mecA gene No No No No No
Susceptibility testing by Etest, mg/L
Penicillin NA NA 0.03 (S) 0.25 (S) 0.06 (S)
Oxacillin 0.06 (S) 0.25 (S) 0.125 (S) 0.125 (S) NA
Ciprofloxacin 0.015 (S) 1.0 (S) 0.5 (S) 4.0 (R) 0.5 (S)
Rifampin 0.015 (S) 0.25 (S) 0.25 (S) 132 (R) 132 (R)
Trimethoprim-sulfamethoxazole 132 (R) 132 (R) 0.06 (S) 0.5 (S) 0.06 (S)
Removal of implant Yes Yes Yes Yes Yes
Antimicrobial agents administered during
implant-free interval
FLUCLOX and RIF LVX and RIF FLUCLOX, switched
to LVX and RIF
FLUCLOX PEN and LVX
Duration of treatment, weeks 6 7 5.5 6 6
Antibiotic-free interval prior to
reimplantation, days
3 15 …d 10 14
Reimplantation Yes Yes No Yes Yes
Follow-up, months 48 13 24 24 12
Outcome Cured Probably cured Cured Cured Probably cured
NOTE. FLUCLOX, flucloxacillin; LVX, levofloxacin; NA, not available; PEN, penicillin; R, resistant; RIF, rifampin; S, susceptible.
a After thawing the frozen strain, SCVs grew after 2 days.
b Joint puncture was not performed.
c Monoculture grew in cultures of synovia. Biopsies obtained during subsequent surgery revealed both phenotypes.
d Patient refused reimplantation of the prosthesis.
isolated by preoperative joint puncture (patient 2) or were not
suspected (patient 3). After detection of SCVs from periprosth-
etic tissue, the spacers were removed in both cases in a second
intervention. Antimicrobial treatment was selected according
to susceptibility testing results and, if possible, a combination
of levofloxacin plus rifampin was administered. Duration of
therapy ranged from 5.5 to 7 weeks. The antibiotic-free interval
prior to reimplantation of the prosthesis ranged from 10 to 14
days in 3 patients. In 1 patient, reimplantation of the prosthesis
was performed after 3 days. One patient refused reimplantation
of the prosthesis because of fear of reinfection. None of the
patients showed signs of infection during their postoperative
course. Duration of follow-up ranged from 12 to 48 months,
with a mean duration of 24 months. According to study def-
initions, 3 patients were cured, and 2 patients were probably
cured.
DISCUSSION
To our knowledge, this is the first report of SCVs associated
with PJI. The ratio of SCV infections to all infections in patients
with total hip arthroplasty was 5:66 during a 4-year period.
The interpretation of this rate is difficult, because 4 of the 5
patients were transferred to our tertiary care center after relapse
occurred or when infection persisted. However, it is conceivable
that SCVs are underestimated as the causative agent in relapsing
or persistent S. aureus infections. Several observations that we
made with this case series may allow a faster diagnosis and a
more efficient treatment of similar cases.
On the basis of the isolation of normal-phenotype S. aureus
from the primary PJI, all patients were initially administered
the correct treatment according to our previously published
algorithm [17]. Patients 1–4 experienced a short duration of
clinical symptoms (3 weeks) and underwent debridement and
adequate antimicrobial treatment; patient 5 presented with a
long duration of clinical symptoms (13 weeks) and was, there-
fore, treated with a 2-stage exchange. Nevertheless, in all cases,
staphylococcal infection persisted or relapse occurred—either
on the side of primary infection or on the contralateral side—
until SCVs were isolated. This emphasizes the hypothesis that
SCVs should be considered as difficult-to-treat microorganisms
and, therefore, treated differently than normal-phenotype S.
aureus. Moreover, in the case of persistence or relapse, one
must actively look for SCVs; a lack of awareness led to inef-
fective surgical revisions and antimicrobial treatment in at least
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Figure 1. Small colony variant (A) and normal-phenotype Staphylo-
coccus aureus (B) isolated from patient 1 on Columbia blood agar.
Figure 2. Transmission electron micrography of a sample obtained from
the hip joint capsule of patient 5 revealing 3 fibroblasts surrounded by
collagen fibers (A). Intracellular cocci are shown in the lower cell of panel
A and in an enlarged image in panel B. Intracellular cocci in a fibroblast
are shown in panel C.
2 of our cases. In patients 1 and 2, unexpected treatment failure
prompted a rapid search for SCVs and the cessation of further
inadequate therapy.
Because SCVs are difficult to treat, all involved foreign ma-
terial must be removed. SCV hemB mutants have been shown
to have a significantly higher rate of adhesion to fibrinogen
and fibronectin than their normal-growing parental strains, and
they are much more resistant to antibiotics when they adhere
to an implant [24]. When SCVs reach a stationary phase after
adherence, they are particularly resistant to antibiotic killing
[25]. Therefore, and in contrast to PJI due to normal-phenotype
S. aureus, a spacer should not be implanted. If SCVs are found
growing in periprosthetic tissue after a spacer has been im-
planted, the spacer should be removed. Extensive tissue de-
bridement is, therefore, required, because SCVs have the ability
to persist intracellularly and also may adhere to sequesters. To
our knowledge, the intracellular persistence of SCVs has been
shown only in vitro [2]. A recently published study demon-
strated the in vivo intracellular persistence of normal-pheno-
type S. aureusin nasal mucosa cells [26]. Our ex vivo investi-
gation of periprosthetic tissue very likely revealed the
intracellular persistence of SCVs, and, therefore, adds signifi-
cant information to previous in vitro findings. However, be-
cause our investigations were conducted with biopsy specimens
obtained from just 1 patient and because control biopsy spec-
imens with normal-phenotype S. aureus are missing, more stud-
ies are needed for in vivo confirmation of published in vitro
results [2]. Nevertheless, the intracellular persistence of bacteria
in fibroblasts was clearly shown, underlining the importance
of meticulous debridement of infected tissue in addition to
antimicrobial treatment.
Decisions regarding antimicrobial agents were based on MIC
testing, because antibiotic disk diffusion tests are known not
to be reliable [27–29]. Although Etests are less reliable than
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broth or agar dilution methods in certain cases [1, 27, 30], they
have been used by others to examine MICs of SCVs [4, 6, 16].
For methicillin-susceptible strains of SCVs, Etests are a partic-
ularly valuable option, because the concentration gradient of
the antimicrobial agent remains stable for several days, and
comparisons of Etests and agar dilution tests have shown a
good correlation for SCVs [6] and other fastidious and slow-
growing bacteria, such as Mycobacterium species [31, 32]. In-
terestingly, 2 pathogens were resistant to trimethoprim-sulfa-
methoxazol without previous exposure. Thymidine-dependent
SCVs have been shown to be resistant to this compound [30,
33], but because auxotrophism tests could not be performed
in these cases because of reversion, this remains a speculation.
One SCV’s subculture revealed resistance to rifampin, and 1
revealed resistance to both ciprofloxacin and rifampin. SCV
hemB mutants are known to acquire resistance to these agents
in the same manner as normal phenotypes (i.e., via mutations
in certain target genes) [34]. Astonishingly, patient 3 was ex-
posed to ciprofloxacin and rifampin for 19 months, but resis-
tance did not arise. However, the clinical courses in patients 4
and 5 indicate that a rifampin-containing regimen without ap-
propriate surgical treatment does not eradicate SCVs and can
result in the emergence of resistance. The optimal treatment
for SCV infection is not known, but our decision to administer
a combination of rifampin plus levofloxacin relied on the find-
ings that the decreased electron gradient across the cell
membrane of SCVs probably does not impair the efficacy of
these agents [35]. For the resistant cases, b-lactams were ad-
ministered, either in combination with levofloxacin or rifampin
or alone.
In conclusion, treatment failure in cases of staphylococcal
PJI despite correct treatment should prompt an active search
for SCVs. This requires a good collaboration between ortho-
pedic surgeons, infectious diseases specialists, microbiologists,
and laboratory technicians. A 2-stage exchange without intro-
duction of any foreign material, combined with antimicrobial
treatment during an implant-free interval of 6–8 weeks, had a
successful outcome, with a mean duration of follow-up of 24
months.
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